Navigation Links
Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
Date:3/13/2008

ng (tCGM) systems for people with diabetes and for use by healthcare professionals in hospital critical care units worldwide.

Cautionary Statement Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward- looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies regarding the efficacy of Echo's tCGM systems, the failure of future development and preliminary marketing efforts related to Echo's tCGM systems, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic products based on its skin permeation platform technologies, the availability of substantial additional equity capital to support robust research, development and product commercialization activities, and the success of research, development, and regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to Echo's tCGM systems. Furthermore, Echo's transdermal continuous glucose monitoring systems have not yet been approved for sale. The regulatory approval process for its tCGM systems involves, among other things, successfully completing clinical trials and obtaining a premarket approval, or PMA, from the FDA. The PMA process requires Echo to prove the safety and efficacy of its tCGM systems to the FDA's satisfaction. This process can be expensive and uncertain, and there is no guarantee that Echo will be able to submit a PMA for its Symphony tCGM System or that its Symphony tCGM System will be approved by the FDA in any specific timefr
'/>"/>

SOURCE Echo Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
2. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
3. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
4. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
5. Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Childrens Hospital at Stanford
6. Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
7. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
8. Prime Therapeutics Introduces Efficiency Program to Help Employers Understand How to Most Effectively Spend Pharmacy Dollars
9. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
10. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
11. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... December 26, 2014 Cooking and ... 3.1 out of 5. This score reflects slightly positive ... of product specialization, low switching costs and a low ... by the low availability of substitutes for cooking and ... of steel and aluminum, key inputs in the production ...
(Date:12/26/2014)... 2014 India Network Foundation, a non-profit ... USA, announced today a new version of “ EasySelect ... the right plan for their visiting parents. The technology ... the selection process when choosing an insurance plan by ... only a few clicks. Many elderly Asian Indian parents ...
(Date:12/25/2014)... This is a professional and in-depth study ... with a focus on the Chinese market. The report ... Sterilizers manufacturers and is a valuable source of guidance ... industry. This report provides a basic overview of the ... this part, the report presents the company profile, product ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... University and Harvard University have collaboratively developed a new theoretical ... sequences, even though there are many obstacles in the way ... in the scientific journal Nature Physics . , In ... so that different cells carry out the right tasks at ...
... important tasks of the immune system is to identify what ... then the body,s own structures will be attacked, the result ... mellitus type 1 or multiple sclerosis. The only way to ... that turn against the body,s own tissue in other ...
... Gen-Probe Incorporated (Nasdaq: GPRO ) announced that shareholders ... of Tepnel by Gen-Probe by the requisite majorities at Court ... of Tepnel shareholders voted in favor of the acquisition, which ... as a "scheme of arrangement" under English law. The ...
... Probiotic Works Naturally to Restore Oral HealthCHICAGO, March ... and Butler(R) brand products, has introduced GUM(R) PerioBalance(TM), ... for oral health. GUM(R) PerioBalance(TM) is available online ... GUM(R) PerioBalance(TM) e-store ( www.periobalance.com ) and at ...
... Health Segment Increases Annual RevenueLOVELAND, Colo., March 16 ... ("Heska" or the "Company") today reported financial results ... December 31, 2008, and year ended December 31, ... , "The poor economic environment had an impact ...
... led by Clifford Goodman, PhD, at the NCCN 14th Annual ... Cancer Care." The panel of experts tackled the spectrum of ... benefit to patients of some of the latest cancer treatments ... Oncology is an area of rapid growth, both in terms ...
Cached Medicine News:Health News:Important new model shows how proteins find the right DNA sequences 2Health News:Dendritic cells ensure immune tolerance 2Health News:Dendritic cells ensure immune tolerance 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 2Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 4Health News:New Probiotic Supplement Helps Consumers Fight Unhealthy Teeth and Gums 2Health News:New Probiotic Supplement Helps Consumers Fight Unhealthy Teeth and Gums 3Health News:Heska Announces Q4 and Annual 2008 Results 2Health News:Heska Announces Q4 and Annual 2008 Results 3Health News:Heska Announces Q4 and Annual 2008 Results 4Health News:Heska Announces Q4 and Annual 2008 Results 5Health News:Heska Announces Q4 and Annual 2008 Results 6Health News:Heska Announces Q4 and Annual 2008 Results 7Health News:Heska Announces Q4 and Annual 2008 Results 8Health News:Heska Announces Q4 and Annual 2008 Results 9Health News:Heska Announces Q4 and Annual 2008 Results 10Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 2Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 3Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 4Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 5
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 /PRNewswire/ ... (NASDAQ: ENDP ) (TSX: ENL), and BioDelivery ... today that they have submitted a New Drug Application ... Food and Drug Administration (FDA).  Buprenorphine HCl Buccal Film ... enough to require daily, around-the-clock, long-term opioid treatment and ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... 22, 2014 Apnea Sciences ( www.apneasciences.com ) ... Aliso Viejo , California.  Jimmy ... tremendous growth and worldwide expansion, a new facility with ... the anti snore cure have exceeded our expectations and ... are now in 23 countries and will be increasing ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... to Show That Extended,Thromboprophylaxis Reduces VTE Risk ... 44% , PARIS, July 8, 2007 /PRNewswire-FirstCall/ ... (EXtended CLinical,prophylaxis in Acutely Ill Medical patients) ... in acutely ill medical patients,with reduced mobility ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Cached Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
Quality control ampoules are specifically developed for Radiometers analyzers , Different parameter profiles (different combinations of blood gases, oximetry, electrolytes and metabolites) , Co...
... In interventional cardiology, accurate ... role, particularly in determining the ... With Interventional Cardiac 3-D (IC3D), ... imaging tool, clinicians are now ...
The AXIOM Artis TC is ideal for applications above and beyond standard cardioangiography, and features:, Single plane C-Arm, ceiling-mounted, Full-size CCD camera, ...
... Hybrid Imaging in Cardiology ... imaging solutions in cardiology. ... coronary CT angiography imaging combined ... Symbia TruePoint SPECTCT combines ...
Medicine Products: